citalopram has been researched along with Arrhythmia in 22 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease." | 9.19 | Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2014) |
| "This was a randomized, double-blind, placebo- and active comparator-controlled study, in which patients (> or = 18 years) meeting DSM-IV criteria for Major Depressive Disorder (MDD) received duloxetine 60 mg once daily (QD; N = 273), escitalopram 10 mg QD (N = 274), or placebo (N = 137) for 8 weeks." | 9.12 | Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. ( Greist, JH; Mallinckrodt, CH; Nierenberg, AA; Prakash, A; Sambunaris, A; Tollefson, GD; Wohlreich, MM, 2007) |
| "The selective serotonin reuptake inhibitors (SSRIs) citalopram and escitalopram are associated with QT prolongation, which increases the risk of serious arrhythmia." | 8.12 | Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population-based cohort study in older adults. ( Aakjaer, M; Andersen, M; De Bruin, ML; Werther, SK, 2022) |
| "The effect of citalopram (CTP) a selective serotonin reuptake inhibitor agent was studied on ouabain-induced arrhythmia in spontaneously beating isolated guinea-pig atria." | 7.72 | Effect of citalopram on ouabain-induced arrhythmia in isolated guinea-pig atria. ( Malihi, G; Naghibi, B; Pousti, A, 2003) |
| "The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease." | 5.19 | Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2014) |
| "This was a randomized, double-blind, placebo- and active comparator-controlled study, in which patients (> or = 18 years) meeting DSM-IV criteria for Major Depressive Disorder (MDD) received duloxetine 60 mg once daily (QD; N = 273), escitalopram 10 mg QD (N = 274), or placebo (N = 137) for 8 weeks." | 5.12 | Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. ( Greist, JH; Mallinckrodt, CH; Nierenberg, AA; Prakash, A; Sambunaris, A; Tollefson, GD; Wohlreich, MM, 2007) |
| "The selective serotonin reuptake inhibitors (SSRIs) citalopram and escitalopram are associated with QT prolongation, which increases the risk of serious arrhythmia." | 4.12 | Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population-based cohort study in older adults. ( Aakjaer, M; Andersen, M; De Bruin, ML; Werther, SK, 2022) |
| "This study compares the risks of arrhythmia among patients with depression receiving selective serotonin reuptake inhibitors (SSRIs) and those receiving other classes of antidepressants and among patients with depression receiving citalopram-escitalopram and those receiving other SSRIs." | 3.91 | Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study. ( Hansen, RA; Lin, YT; Lu, TS; Wang, CC, 2019) |
| "Citalopram daily doses >40 mg were associated with lower risks of ventricular arrhythmia (adjusted hazard ratio=0." | 3.79 | Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. ( Blow, FC; Bohnert, AS; Ganoczy, D; Kales, HC; Nallamothu, BK; Pfeiffer, PN; Zivin, K, 2013) |
| " In the first case, the drugs venlafaxine, amiodarone and domperidone may have contributed to QT interval prolongation in a patient with hypokalemia and hypomagnesaemia." | 3.76 | Multifactorial QT interval prolongation. ( Baranchuk, A; Digby, G; Machaalany, J; Malik, P; Methot, M; Redfearn, D; Simpson, CS, 2010) |
| " A 52-year-old man with a history of depression treated with escitalopram 10 mg/day, extended-release morphine 30 mg/day and zopiclone 15 mg/day was found unconscious at his home." | 3.74 | Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. ( Baranchuk, A; Gibson, K; Methot, M; Simpson, CS; Strum, D, 2008) |
| "The effect of citalopram (CTP) a selective serotonin reuptake inhibitor agent was studied on ouabain-induced arrhythmia in spontaneously beating isolated guinea-pig atria." | 3.72 | Effect of citalopram on ouabain-induced arrhythmia in isolated guinea-pig atria. ( Malihi, G; Naghibi, B; Pousti, A, 2003) |
| "The risk of arrhythmia may be increased with concomitant use of other drugs that induce QT prolongation." | 1.51 | Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs. ( Beaussier, H; Bézie, Y; Chastang, A; Corny, J; Lillo-Lelouet, A; Petre, A; Phan Thi, TT; Renet, S, 2019) |
| "Although the US Food and Drug Administration (FDA) recommended upper limits for citalopram dosing in older adults due to risk of corrected-QT (QTc) prolongation, which was adopted, and extended to escitalopram by Health Canada, the scientific basis is unclear." | 1.51 | Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting. ( Brown, HK; Crépeau-Gendron, G; Koh, S; Madan, R; Mah, L; Shorey, C; Szabuniewicz, C; Veinish, S, 2019) |
| "Escitalopram has a small effect on the QTc interval." | 1.38 | A question about the potential cardiac toxicity of escitalopram. ( Howland, RH, 2012) |
| "There were no deaths, seizures, or arrhythmias." | 1.35 | Clinical and ECG effects of escitalopram overdose. ( Isbister, GK; van Gorp, F; Whyte, IM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, L | 1 |
| Sun, H | 1 |
| Aakjaer, M | 1 |
| Werther, SK | 1 |
| De Bruin, ML | 1 |
| Andersen, M | 1 |
| Czaja, AS | 1 |
| Anderson, HD | 1 |
| Ghosh, D | 1 |
| Davidson, J | 1 |
| Campbell, JD | 1 |
| Valuck, RJ | 1 |
| Ojero-Senard, A | 1 |
| Benevent, J | 1 |
| Bondon-Guitton, E | 1 |
| Durrieu, G | 1 |
| Chebane, L | 1 |
| Araujo, M | 1 |
| Montastruc, F | 1 |
| Montastruc, JL | 1 |
| Farkas, AN | 1 |
| Marcott, M | 1 |
| Yanta, JH | 1 |
| Pizon, AF | 1 |
| Chastang, A | 1 |
| Renet, S | 1 |
| Corny, J | 1 |
| Beaussier, H | 1 |
| Petre, A | 1 |
| Lillo-Lelouet, A | 1 |
| Phan Thi, TT | 1 |
| Bézie, Y | 1 |
| Crépeau-Gendron, G | 1 |
| Brown, HK | 1 |
| Shorey, C | 1 |
| Madan, R | 1 |
| Szabuniewicz, C | 1 |
| Koh, S | 1 |
| Veinish, S | 1 |
| Mah, L | 1 |
| Lin, YT | 1 |
| Lu, TS | 1 |
| Hansen, RA | 1 |
| Wang, CC | 1 |
| Zivin, K | 1 |
| Pfeiffer, PN | 1 |
| Bohnert, AS | 1 |
| Ganoczy, D | 1 |
| Blow, FC | 1 |
| Nallamothu, BK | 1 |
| Kales, HC | 1 |
| Wang, SM | 1 |
| Pae, CU | 1 |
| Porsteinsson, AP | 1 |
| Drye, LT | 1 |
| Pollock, BG | 1 |
| Devanand, DP | 1 |
| Frangakis, C | 1 |
| Ismail, Z | 1 |
| Marano, C | 1 |
| Meinert, CL | 1 |
| Mintzer, JE | 1 |
| Munro, CA | 1 |
| Pelton, G | 1 |
| Rabins, PV | 1 |
| Rosenberg, PB | 1 |
| Schneider, LS | 1 |
| Shade, DM | 1 |
| Weintraub, D | 1 |
| Yesavage, J | 1 |
| Lyketsos, CG | 1 |
| Kumar, Y | 1 |
| Kung, S | 1 |
| Shinozaki, G | 1 |
| Zhang, Y | 1 |
| Baranchuk, A | 3 |
| Hancox, JC | 1 |
| Gioia, S | 1 |
| Lancia, M | 1 |
| Bacci, M | 1 |
| Suadoni, F | 1 |
| Simpson, CS | 2 |
| Methot, M | 2 |
| Gibson, K | 1 |
| Strum, D | 1 |
| van Gorp, F | 1 |
| Whyte, IM | 1 |
| Isbister, GK | 1 |
| Digby, G | 1 |
| Machaalany, J | 1 |
| Malik, P | 1 |
| Redfearn, D | 1 |
| Howland, RH | 2 |
| Pousti, A | 1 |
| Malihi, G | 1 |
| Naghibi, B | 1 |
| Vinter, S | 1 |
| Isaksen, C | 1 |
| Vesterby, A | 1 |
| Nierenberg, AA | 1 |
| Greist, JH | 1 |
| Mallinckrodt, CH | 1 |
| Prakash, A | 1 |
| Sambunaris, A | 1 |
| Tollefson, GD | 1 |
| Wohlreich, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease[NCT00898807] | Phase 3 | 186 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression[NCT00073411] | Phase 3 | 675 participants | Interventional | 2003-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CMAI examines several agitated behaviors including verbal, physical agitation, and other behaviors. Sub-items are summed. Range is 14-70. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 27.7 |
| Placebo and Psychosocial Intervention | 28.7 |
"Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in agitation(CGIC) accesses clinically significant change in agitation. A trained clinician, blind to treatment assignment, uses a 7-point Likert scale to rate change of each patient along a continuum from marked improvement(1), no change(4), and marked worsening(7). A number of aspects of the agitation is considered such as emotional agitation, mood liability/distress, psychomotor agitation, verbal aggression, and physical aggression. Range is 1-7." (NCT00898807)
Timeframe: Baseline to 9 weeks
| Intervention | percentage moderate/marked improvement (Number) |
|---|---|
| Citalopram and Psychosocial Intervention | 40 |
| Placebo and Psychosocial Intervention | 26 |
NeuroBehavioral Rating Scale- Agitation(NBRS-A) assesses multiple types of psychopathology common in dementia and is based on a seven point Likert scale of increasing severity for each item(i.e., 0=not present, 1=very mild, 2-mild, 3=moderate, 4=moderately severe, 5=severe, 6=extremely severe). The NBRS agitation subscore includes NBRS 'inhibition', 'agitation', and 'hostility'. The range is 0 to 18 points. Higher scores indicate more symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 4.33 |
| Placebo and Psychosocial Intervention | 5.26 |
NPI agitation score is based on responses from an informed caregiver involved in the patient's life. Symptom severity (1=mild, 2=moderate, 3=severe) is multiplied by frequency (1=occasionally, less than once/week; 4 = very frequently, once or more/day or continuously) to obtain the NPI agitation score.Range is 0-12. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 7.8 |
| Placebo and Psychosocial Intervention | 8.0 |
2 reviews available for citalopram and Arrhythmia
| Article | Year |
|---|---|
How much to worry about the FDA warning in the use of citalopram?
Topics: Antidepressive Agents, Second-Generation; Arrhythmias, Cardiac; Citalopram; Humans; United States; U | 2013 |
Towards limiting QT interval prolongation and arrhythmia risk in citalopram use.
Topics: Arrhythmias, Cardiac; Citalopram; Depression; Electrocardiography; Global Health; Humans; Incidence; | 2014 |
2 trials available for citalopram and Arrhythmia
| Article | Year |
|---|---|
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Arrhythmias, Cardiac; Caregi | 2014 |
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Topics: Adult; Antidepressive Agents; Arrhythmias, Cardiac; Citalopram; Depressive Disorder; Double-Blind Me | 2007 |
18 other studies available for citalopram and Arrhythmia
| Article | Year |
|---|---|
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant | 2008 |
Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population-based cohort study in older adults.
Topics: Aged; Arrhythmias, Cardiac; Citalopram; Cohort Studies; Escitalopram; Humans; Selective Serotonin Re | 2022 |
Increased Odds of Ventricular Arrhythmias Associated with Selective Serotonin Reuptake Inhibitor Use among the Pediatric and Young Adult Population: A Case-Control Study.
Topics: Adolescent; Age Factors; Arrhythmias, Cardiac; Case-Control Studies; Child; Child, Preschool; Citalo | 2020 |
A comparative study of QT prolongation with serotonin reuptake inhibitors.
Topics: Adult; Aged; Arrhythmias, Cardiac; Citalopram; Databases, Factual; Female; Fluvoxamine; Humans; Long | 2017 |
Bicarbonate refractory QRS prolongation and left bundle-branch block following escitalopram and lamotrigine overdose: A case report and literature review of toxic left bundle-branch block.
Topics: Adult; Arrhythmias, Cardiac; Bicarbonates; Bundle-Branch Block; Citalopram; Electrocardiography; Fem | 2018 |
Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antipsychotic Agents; Arrhythmias, Cardiac; Citalopram; Drug In | 2019 |
Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting.
Topics: Aged; Arrhythmias, Cardiac; Citalopram; Electrocardiography; Electronic Health Records; Female; Heal | 2019 |
Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study.
Topics: Antidepressive Agents; Arrhythmias, Cardiac; Citalopram; Depression; Humans; Retrospective Studies; | 2019 |
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Citalopram; Depressive Disorder; Female; Heart | 2013 |
CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.
Topics: Adult; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Citalopram; Cytoch | 2014 |
A Fatal Case of Acute Butane-Propane Poisoning in a Prisoner Under Psychiatric Treatment: Do These 2 Factors Have an Arrhythmogenic Interaction, Thus Increasing the Cardiovascular Risk Profile?
Topics: Adult; Antipsychotic Agents; Arrhythmias, Cardiac; Butanes; Chlorpromazine; Citalopram; Drug Interac | 2015 |
Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines.
Topics: Antidepressive Agents, Second-Generation; Arrhythmias, Cardiac; Azabicyclo Compounds; Benzodiazepine | 2008 |
Clinical and ECG effects of escitalopram overdose.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Citalopram; Dose-Response Relationship, Drug; Drug Interact | 2009 |
Multifactorial QT interval prolongation.
Topics: Alcoholism; Amiodarone; Antipsychotic Agents; Arrhythmias, Cardiac; Biomarkers; Citalopram; Cyclohex | 2010 |
A critical evaluation of the cardiac toxicity of citalopram: part 2.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Citalopram; Cytochrome P-450 Enzyme System; Dose-Resp | 2011 |
A question about the potential cardiac toxicity of escitalopram.
Topics: Arrhythmias, Cardiac; Citalopram; Humans; Long QT Syndrome; Selective Serotonin Reuptake Inhibitors; | 2012 |
Effect of citalopram on ouabain-induced arrhythmia in isolated guinea-pig atria.
Topics: Animals; Arrhythmias, Cardiac; Citalopram; Dose-Response Relationship, Drug; Drug Interactions; Fema | 2003 |
Sudden cardiac death in a young woman: tumor of the atrioventricular (AV) node or citalopram intoxication?
Topics: Adult; Antibodies, Neoplasm; Antidepressive Agents, Second-Generation; Arrhythmias, Cardiac; Atriove | 2005 |